Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 198

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 198
---
2 and $6 from a related party)5 20 Other assets ($— and $6 from a related party)(1)15 Accounts payable (($13) and $— to a related party)11 (1)Deferred revenue (($188) and ($90) to a related party)(188)(81)Other liabilities(12)(9)Net cash used in operating activities(265)(96) Cash flow from investing activitiesPurchases of marketable securities(514)(593)Proceeds from maturities of marketable securities615 484 Proceeds from sales of marketable securities69 7 Purchases of property and equipment(1)(4)Net cash provided by (used in) investing activities169 (106) Cash flow from financing activitiesProceeds from issuance of common stock ($14 and $228 from a related party)142 228 Proceeds from debt issuances, net49 — Proceeds from issuance of common stock pursuant to equity award plans3 4 Payments of employee taxes related to net settlement of equity awards— (1)Net cash provided by financing activities194 231 Net increase in cash, cash equivalents and restricted cash98 29 Cash, cash equivalents and restricted cash at beginning of period153 130 Cash, cash equivalents and restricted cash at end of period$251 $159 

See accompanying notes.

5

ARCUS BIOSCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Note 1. Organization, liquidity and capital resources

Organization Arcus Biosciences, Inc. (referred to as "Arcus," "we," "our," "us," or the "Company") is a clinical-stage biopharmaceutical company focused on creating best-in-class therapies. Using our robust and highly efficient drug discovery capability, we have created a significant portfolio of investigational products which are in clinical development, with our most advanced molecule, an anti-TIGIT antibody, now in multiple Phase 3 registrational studies targeting lung and gastrointestinal ("GI") cancers. Our deep portfolio of novel small molecules and enabling antibodies allows us to create highly differentiated therapies, which we are developing to treat multiple large indications.We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. See Note 15, Business segment, for more information.Liquidity and Capital ResourcesAs of June